Organon & Co. Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent
Organon & Co. (OGN) reported Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent of -$9.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent · last filed 2026-07-31
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2026-06-30 was -$9.00M, a 120.00% decline year-over-year.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2026-03-31 was -$12.00M, a 137.50% decline year-over-year.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2025-12-31 was $52.00M.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for the quarter ending 2025-09-30 was -$2.00M, a 104.88% decline year-over-year.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2025 was $127.00M.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2024 was -$109.00M, a 673.68% decline from fiscal 2023.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2023 was $19.00M.
- Organon & Co. other comprehensive income (loss), before tax, portion attributable to parent for fiscal 2022 was -$46.00M, a 141.44% decline from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.00M 10-Q · filed 2026-07-31 | -$21.00M 10-Q · filed 2026-07-31 | $31.00M derived: sum of 3 quarters · filed 2026-07-31 | $29.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | -$12.00M 10-Q · filed 2026-05-04 | $40.00M derived: sum of 2 quarters · filed 2026-05-04 | $38.00M derived: sum of 3 quarters · filed 2026-05-04 | $83.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $52.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $50.00M derived: sum of 2 quarters · filed 2026-02-24 | $95.00M derived: sum of 3 quarters · filed 2026-07-31 | $127.00M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$2.00M 10-Q · filed 2025-11-10 | $43.00M derived: sum of 2 quarters · filed 2026-07-31 | $75.00M 10-Q · filed 2025-11-10 | -$4.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $45.00M 10-Q · filed 2026-07-31 | $77.00M 10-Q · filed 2026-07-31 | -$2.00M derived: sum of 3 quarters · filed 2026-07-31 | $39.00M derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $32.00M 10-Q · filed 2026-05-04 | -$47.00M derived: sum of 2 quarters · filed 2026-05-04 | -$6.00M derived: sum of 3 quarters · filed 2026-05-04 | -$41.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$79.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$38.00M derived: sum of 2 quarters · filed 2026-02-24 | -$73.00M derived: sum of 3 quarters · filed 2026-02-24 | -$109.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $41.00M 10-Q · filed 2025-11-10 | $6.00M derived: sum of 2 quarters · filed 2025-11-10 | -$30.00M 10-Q · filed 2025-11-10 | $1.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$35.00M 10-Q · filed 2025-08-06 | -$71.00M 10-Q · filed 2025-08-06 | -$40.00M derived: sum of 3 quarters · filed 2026-02-24 | -$83.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$36.00M 10-Q · filed 2025-05-02 | -$5.00M derived: sum of 2 quarters · filed 2026-02-24 | -$48.00M derived: sum of 3 quarters · filed 2026-02-24 | -$47.00M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$12.00M derived: sum of 2 quarters · filed 2026-02-24 | -$11.00M derived: sum of 3 quarters · filed 2026-02-24 | $19.00M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$43.00M 10-Q · filed 2024-11-01 | -$42.00M derived: sum of 2 quarters · filed 2024-11-01 | -$12.00M 10-Q · filed 2024-11-01 | $116.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $1.00M 10-Q · filed 2024-08-07 | $31.00M 10-Q · filed 2024-08-07 | $159.00M derived: sum of 3 quarters · filed 2025-02-28 | $62.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $30.00M 10-Q · filed 2024-05-03 | $158.00M derived: sum of 2 quarters · filed 2025-02-28 | $61.00M derived: sum of 3 quarters · filed 2025-02-28 | $0.00 derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $128.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $31.00M derived: sum of 2 quarters · filed 2025-02-28 | -$30.00M derived: sum of 3 quarters · filed 2025-02-28 | -$46.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$97.00M 10-Q · filed 2023-11-03 | -$158.00M derived: sum of 2 quarters · filed 2023-11-03 | -$174.00M 10-Q · filed 2023-11-03 | -$191.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$61.00M 10-Q · filed 2023-08-09 | -$77.00M 10-Q · filed 2023-08-09 | -$94.00M derived: sum of 3 quarters · filed 2024-02-26 | -$120.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$16.00M 10-Q · filed 2023-05-05 | -$33.00M derived: sum of 2 quarters · filed 2024-02-26 | -$59.00M derived: sum of 3 quarters · filed 2024-02-26 | $159.00M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$43.00M derived: sum of 2 quarters · filed 2024-02-26 | $175.00M derived: sum of 3 quarters · filed 2024-02-26 | $111.00M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$26.00M 10-Q · filed 2022-11-04 | $192.00M derived: sum of 2 quarters · filed 2022-11-04 | $128.00M 10-Q · filed 2022-11-04 | $0.00 derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $218.00M 10-Q · filed 2022-08-05 | $154.00M 10-Q · filed 2022-08-05 | $26.00M derived: sum of 3 quarters · filed 2023-02-27 | $70.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$65.00M 10-Q · filed 2022-05-06 | -$192.00M derived: sum of 2 quarters · filed 2023-02-27 | -$148.00M derived: sum of 3 quarters · filed 2023-02-27 | -$119.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$127.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$83.00M derived: sum of 2 quarters · filed 2023-02-27 | -$54.00M derived: sum of 3 quarters · filed 2023-02-27 | -$202.00M 10-K · filed 2023-02-27 |
| 2020-09-30 | $44.00M 10-Q · filed 2021-11-12 | $73.00M derived: sum of 2 quarters · filed 2021-11-12 | -$75.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $29.00M 10-Q · filed 2021-08-16 | -$119.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$148.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | -$14.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |